Search results
Results from the WOW.Com Content Network
EMA/199678/2016: Reflection paper on extrapolation of efficacy and safety in paediatric medicine development. [8] EMA/189724/2018: Reflection paper on the use of extrapolation in the development of medicines for paediatrics. [9] EMA/129698/2012: Concept paper on extrapolation of efficacy and safety in medicine development. [10]
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.
A drug is considered highly soluble when the highest dose strength is soluble in 250 ml or less of aqueous media over the pH range of 1 to 6.8. The volume estimate of 250 ml is derived from typical bioequivalence study protocols that prescribe administration of a drug product to fasting human volunteers with a glass of water.
Notwithstanding the above knowledge, a 1994 Diabetes Care article by Mary M. Tai purports to have independently discovered the trapezoidal rule. [9] In Tai's response to the later letters to the editors, she explained that the rule was new to her colleagues, who relied on grid-counting. [10]
The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency ( EMEA ).
The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate and partial agreement of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia (an international treaty adopted by the Council of Europe in 1964: ETS 50, [2] Protocol [3]).
A very simple equivalence testing approach is the ‘two one-sided t-tests’ (TOST) procedure. [11] In the TOST procedure an upper (Δ U) and lower (–Δ L) equivalence bound is specified based on the smallest effect size of interest (e.g., a positive or negative difference of d = 0.3).
It is a non-insulin-based alternative to insulin-based methods to quantify peripheral insulin sensitivity and an alternative to SPINA Carb, the Homeostatic Model Assessment (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI). METS-IR is currently validated for its use to assess cardio-metabolic risk in Latino population.